JP7214350B2 - 光及びポリカルボン酸を使用して皮膚疾患を治療するための組成物及び方法 - Google Patents
光及びポリカルボン酸を使用して皮膚疾患を治療するための組成物及び方法 Download PDFInfo
- Publication number
- JP7214350B2 JP7214350B2 JP2018019867A JP2018019867A JP7214350B2 JP 7214350 B2 JP7214350 B2 JP 7214350B2 JP 2018019867 A JP2018019867 A JP 2018019867A JP 2018019867 A JP2018019867 A JP 2018019867A JP 7214350 B2 JP7214350 B2 JP 7214350B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- light
- kit
- film
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0034—Skin treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、少なくとも1種類のC2~C5ポリカルボン酸を含む局所適用組成物を用いる。本組成物は、1種類以上のC2~C5ポリカルボン酸を含んでよい。
本光送達装置は、400nm~460nm、好ましくは430nm~450nmのピーク波長を有する青色光の任意の光源を備えてよい。これは、400nm~460nmのピーク波長を有する青色光を放射するのであれば、任意の形態又は構成であってよい。青色光は、連続的に、パルス状で、集中的に、拡散して、多波長で、コヒーレントに、若しくは所望の範囲内で非コヒーレントに、又は単一波長で送達されてよい。
本発明によると、C2~C5ポリカルボン酸及び青色光の組み合わせの投与は、更なる抗菌活性、具体的には抗P.アクネス活性をもたらす。このような組み合わせは、コハク酸の局所投与のみ、又は青色光への曝露のみのいずれかによって示される抗P.アクネス活性に対して、相乗的な抗P.アクネス活性をもたらすことが見出されている。
様々な試験治療の抗P.アクネス活性を比較した。抗P.アクネス活性は、上記のインビトロ法を使用して測定した。試験治療は、440nmの青色光を投与した、又は投与しなかった、強化クロストリジウム培地内の0.1又は0.25重量%のいずれかのコハク酸を含んだ。抗P.アクネス活性は、未治療の強化クロストリジウム培地対照についても調査した。非対照試験試料は、pH4.5に調整した。
表2及び3に示す成分を使用して、コハク酸及びグリセリンを含有する、本発明による以下の局所適用組成物を調製した。
ヒトの皮膚表面に似たポリメチルメタクリレート(PMMA)プレート(HelioScreen LabsからのHELIOPLATE HD6)を通過するように、440nmの波長及び0.8mW/cm2の強度を有する青色光を方向付けた。プレートを貫通する光の強度は、Newport Power Meter(モデル1936-R)を使用して測定し、表2に記載の局所適用組成物を使用して、1μL/cm2の厚さでプレートをコーティングする前後と比較した。結果を表4に示す。
(1) (a)最大約5重量%の少なくとも1種類のC2~C5ポリカルボン酸を含む局所適用組成物と、(b)400nm~460nmのピーク波長を有する青色光を送達する光送達装置と、を備えるキット。
(2) 前記局所適用組成物は、最大約1重量%の前記ポリカルボン酸を含む、実施態様1に記載のキット。
(3) 前記ポリカルボン酸はコハク酸である、実施態様1に記載のキット。
(4) 前記ポリカルボン酸は-1.52~0.33の油/水分配係数を有する、実施態様1に記載のキット。
(5) 前記ポリカルボン酸は可視光範囲内の主な吸収がない、実施態様1に記載のキット。
(7) 前記局所適用組成物は3.5~5.5のpHを有する、実施態様1に記載のキット。
(8) 前記送達される光の強度は約20mW/cm2未満である、実施態様1に記載のキット。
(9) 前記送達される光の強度は約2mW/cm2未満である、実施態様1に記載のキット。
(10) 前記光送達装置は超音波エネルギーも送達する、実施態様1に記載のキット。
Claims (11)
- 皮膚疾患を治療するためのキットであって、(a)C2~C5ポリカルボン酸としてのコハク酸を、約1重量%以下で含む局所適用組成物と、(b)400nm~460nmのピーク波長を有する青色光を送達する光送達装置と、を備えるキット。
- 前記局所適用組成物は、コハク酸を、約0.25重量%以下で含む、請求項1に記載のキット。
- 前記ポリカルボン酸は-1.52~0.33の油/水分配係数を有する、請求項1又は2に記載のキット。
- 前記ポリカルボン酸は可視光範囲内の主な吸収がない、請求項1~3のいずれか一項に記載のキット。
- 前記局所適用組成物は約4~約20重量%のグリセリンを含む、請求項2に記載のキット。
- 前記局所適用組成物は3.5~5.5のpHを有する、請求項5に記載のキット。
- 送達される前記青色光の強度は約20mW/cm2未満である、請求項1~6のいずれか一項に記載のキット。
- 送達される前記青色光の強度は約2mW/cm2未満である、請求項1~7のいずれか一項に記載のキット。
- 前記光送達装置は超音波エネルギーも送達する、請求項1~8のいずれか一項に記載のキット。
- 前記局所適用組成物はフィルムに含有されている、請求項1~9のいずれか一項に記載のキット。
- 前記局所適用組成物は、コハク酸を、約0.1重量%以下で含む、請求項1~10のいずれか一項に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/427,434 | 2017-02-08 | ||
US15/427,434 US10596134B2 (en) | 2017-02-08 | 2017-02-08 | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018127449A JP2018127449A (ja) | 2018-08-16 |
JP7214350B2 true JP7214350B2 (ja) | 2023-01-30 |
Family
ID=61188686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018019867A Active JP7214350B2 (ja) | 2017-02-08 | 2018-02-07 | 光及びポリカルボン酸を使用して皮膚疾患を治療するための組成物及び方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10596134B2 (ja) |
EP (1) | EP3360598B1 (ja) |
JP (1) | JP7214350B2 (ja) |
KR (1) | KR102631501B1 (ja) |
CN (1) | CN108392629B (ja) |
AU (1) | AU2018200900B2 (ja) |
BR (1) | BR102018002462A8 (ja) |
CA (1) | CA2992474A1 (ja) |
ES (1) | ES2794901T3 (ja) |
RU (1) | RU2761343C2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596134B2 (en) * | 2017-02-08 | 2020-03-24 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
US10537534B1 (en) * | 2019-06-25 | 2020-01-21 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using visible light and resorcinols |
CN113905715A (zh) | 2019-06-28 | 2022-01-07 | 宝洁公司 | 光增强处理方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6223071B1 (en) | 1998-05-01 | 2001-04-24 | Dusa Pharmaceuticals Inc. | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
SE9801647D0 (sv) * | 1998-05-12 | 1998-05-12 | Interhealth Ab | Therapeutic composition |
KR100870257B1 (ko) * | 1999-06-25 | 2008-11-25 | 더 프록터 앤드 갬블 캄파니 | 국소용 항미생물 조성물 |
US20030009158A1 (en) | 2001-07-09 | 2003-01-09 | Perricone Nicholas V. | Skin treatments using blue and violet light |
WO2008063441A2 (en) | 2006-11-16 | 2008-05-29 | The Procter & Gamble Company | Personal care composition |
KR20090001013A (ko) * | 2007-06-29 | 2009-01-08 | 주식회사 웰스킨 | 인돌-3-알킬카복실산을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트 |
US10092770B2 (en) | 2011-09-08 | 2018-10-09 | Johnson & Johnson Consumer Inc. | Light therapy spot applicator |
US8771328B2 (en) | 2011-09-08 | 2014-07-08 | La Lumiere Llc | Light therapy platform system |
US9533171B2 (en) | 2012-06-15 | 2017-01-03 | L'oreal | Method for treating acne |
US9408790B2 (en) | 2012-12-11 | 2016-08-09 | Elc Management Llc | Cosmetic compositions with near infra-red (NIR) light-emitting material and methods therefor |
RU2557894C2 (ru) * | 2013-10-18 | 2015-07-27 | Общество с ограниченной ответственностью "Фарма Ген" (ООО "Фарма Ген") | Косметическое средство для быстрого восстановления кожи |
RU2676288C2 (ru) | 2013-12-31 | 2018-12-27 | Джонсон энд Джонсон Консьюмер Инк. | Способ формирования многослойного формованного пленочного продукта в один проход |
CA2935191C (en) | 2013-12-31 | 2021-11-09 | Johnson & Johnson Consumer Inc. | Process for forming a shaped film product |
RU2678037C2 (ru) | 2013-12-31 | 2019-01-22 | Джонсон энд Джонсон Консьюмер Инк. | Процесс формирования многослойной имеющей форму пленки |
US20150182991A1 (en) | 2013-12-31 | 2015-07-02 | Johnson & Johnson Consumer Companies, Inc. | Process for forming an integral film product |
US9474699B2 (en) * | 2014-03-31 | 2016-10-25 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of a basic benefit agent |
BR112017027750B8 (pt) | 2015-06-22 | 2022-08-09 | Johnson & Johnson Consumer Inc | Artigo de múltiplas camadas aplicado topicamente para fornecer um benefício cosmético e/ou terapêutico sobre a pele, método não-terapêutico para fornecer um benefício cosmético à pele e agente terapêutico |
US10596134B2 (en) * | 2017-02-08 | 2020-03-24 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
-
2017
- 2017-02-08 US US15/427,434 patent/US10596134B2/en active Active
-
2018
- 2018-01-22 CA CA2992474A patent/CA2992474A1/en active Pending
- 2018-02-05 CN CN201810111985.3A patent/CN108392629B/zh active Active
- 2018-02-06 KR KR1020180014453A patent/KR102631501B1/ko active IP Right Grant
- 2018-02-06 BR BR102018002462A patent/BR102018002462A8/pt active Search and Examination
- 2018-02-06 RU RU2018104449A patent/RU2761343C2/ru active
- 2018-02-07 AU AU2018200900A patent/AU2018200900B2/en active Active
- 2018-02-07 JP JP2018019867A patent/JP7214350B2/ja active Active
- 2018-02-08 EP EP18155767.9A patent/EP3360598B1/en active Active
- 2018-02-08 ES ES18155767T patent/ES2794901T3/es active Active
-
2020
- 2020-02-13 US US16/790,001 patent/US10973789B2/en active Active
Non-Patent Citations (3)
Title |
---|
FEMS Immunology and Medical Microbiology,2003年,35,pp.17-24 |
J. Clin. Aesthet. Dermatol.,2012年,5(5),pp.25-31 |
化学と生物,1972年,10(12) ,pp.770-778 |
Also Published As
Publication number | Publication date |
---|---|
CA2992474A1 (en) | 2018-08-08 |
AU2018200900A1 (en) | 2018-08-23 |
BR102018002462A8 (pt) | 2022-07-26 |
JP2018127449A (ja) | 2018-08-16 |
KR20180092286A (ko) | 2018-08-17 |
EP3360598A1 (en) | 2018-08-15 |
RU2018104449A3 (ja) | 2021-06-01 |
RU2761343C2 (ru) | 2021-12-07 |
US10973789B2 (en) | 2021-04-13 |
US20180221318A1 (en) | 2018-08-09 |
US20200179318A1 (en) | 2020-06-11 |
EP3360598B1 (en) | 2020-03-25 |
ES2794901T3 (es) | 2020-11-19 |
RU2018104449A (ru) | 2019-08-06 |
AU2018200900B2 (en) | 2023-05-18 |
CN108392629A (zh) | 2018-08-14 |
CN108392629B (zh) | 2022-06-14 |
KR102631501B1 (ko) | 2024-02-01 |
BR102018002462A2 (pt) | 2018-10-30 |
US10596134B2 (en) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10973789B2 (en) | Compositions and methods for treating skin conditions using light and polycarboxylic acids | |
US20060222689A1 (en) | Skin care compositions and methods | |
EP3586926B1 (en) | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride | |
US20190358327A1 (en) | Biophotonic compositions comprising lichen extract and their use to treat skin disorders | |
CA2525465A1 (en) | Topical composition for transdermal administration | |
RU2813118C2 (ru) | Композиции и способы лечения кожных патологий с использованием видимого света и резорцинов | |
JP7483331B2 (ja) | 光及びグルコサミン塩酸塩を使用して皮膚状態を治療するための組成物及び方法 | |
US10537534B1 (en) | Compositions and methods for treating skin conditions using visible light and resorcinols | |
RU2793250C2 (ru) | Композиция и способы лечения патологических состояний кожи; использование света и гидрохлорида глюкозамина | |
JP2021004238A (ja) | 赤外光及びレゾルシノールを使用して皮膚の状態を処置するための組成物及び方法 | |
JP2007016025A (ja) | 皮膚の局部組成物及び方法 | |
TWI325324B (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210107 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220517 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20220627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221207 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7214350 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |